X4 Pharmaceuticals Business Summary

X4 Pharmaceuticals, Inc. (XFOR) is a commercial-stage biopharmaceutical company specializing in the development of oral small-molecule therapeutics for rare diseases of the immune system. The company generates revenue through a dual-stream model: direct product sales of its FDA-approved lead asset, XOLREMDI (mavorixafor), for the treatment of WHIM syndrome in the United States, and strategic licensing agreements, most notably a high-value partnership with Norgine for commercialization in Europe and other global territories. X4 is currently focused on expanding its market footprint by advancing mavorixafor through the Phase 3 4WARD clinical trial for chronic neutropenic disorders, a significantly larger indication. Within the competitive landscape, X4 contends with established therapies such as Amgen’s G-CSF (and its biosimilars) and Sanofi’s Plerixafor, as well as clinical-stage peers like Biohaven and Inhibrx; however, X4 distinguishes itself as a leader in the development of oral, once-daily CXCR4 antagonists specifically tailored for primary immunodeficiencies. Following a major strategic pivot in late 2025, the company is led by a veteran executive team with a proven track record in life sciences turnarounds and successful exits. The leadership is anchored by Executive Chairman Dr. Adam Craig, President John Volpone, and Chief Financial Officer David Kirske—a trio that previously spearheaded the restructuring and $1.7 billion acquisition of CTI BioPharma by Sobi. This management team oversees a streamlined operation focused on clinical execution and commercial scaling. X4 is backed by a sophisticated roster of institutional investors, including Bain Capital Life Sciences, New Enterprise Associates (NEA), and Coastlands Capital, and maintains a board of directors featuring prominent industry figures such as Lead Independent Director Michael Wyzga, formerly of Genzyme and Sanofi.